Top

Published in:

Open Access 01-12-2022 | Lung Cancer | Review

The effects of epithelial–mesenchymal transitions in COPD induced by cigarette smoke: an update

Authors: Xiaoshan Su, Weijing Wu, Zhixing Zhu, Xiaoping Lin, Yiming Zeng

Published in: Respiratory Research | Issue 1/2022

Abstract

Cigarette smoke is a complex aerosol containing a large number of compounds with a variety of toxicity and carcinogenicity. Long-term exposure to cigarette smoke significantly increases the risk of a variety of diseases, including chronic obstructive pulmonary disease (COPD) and lung cancer. Epithelial–mesenchymal transition (EMT) is a unique biological process, that refers to epithelial cells losing their polarity and transforming into mobile mesenchymal cells, playing a crucial role in organ development, fibrosis, and cancer progression. Numerous recent studies have shown that EMT is an important pathophysiological process involved in airway fibrosis, airway remodeling, and malignant transformation of COPD. In this review, we summarized the effects of cigarette smoke on the development and progression of COPD and focus on the specific changes and underlying mechanisms of EMT in COPD induced by cigarette smoke. We spotlighted the signaling pathways involved in EMT induced by cigarette smoke and summarize the current research and treatment approaches for EMT in COPD, aiming to provide ideas for potential new treatment and research directions.

Global Strategy for Prevention, Diagnosis and Management of COPD: 2022 report. In: Global Initiative for Chronic Obstructive Lung Disease—GOLD. https://goldcopd.org/2022-gold-reports-2/.

Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128. https://doi.org/10.1016/S0140-6736(12)61728-0.CrossRefPubMed

Halpin DMG, Celli BR, Criner GJ, et al. The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries. Int J Tuberc Lung Dis. 2019;23:1131–41. https://doi.org/10.5588/ijtld.19.0397.CrossRefPubMed

Hou W, Hu S, Li C, et al. Cigarette smoke induced lung barrier dysfunction, EMT, and tissue remodeling: a possible link between COPD and lung cancer. Biomed Res Int. 2019;2019:2025636. https://doi.org/10.1155/2019/2025636.CrossRefPubMedPubMedCentral

Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med. 2016;374:1811–21. https://doi.org/10.1056/NEJMoa1505971.CrossRefPubMedPubMedCentral

Kohansal R, Martinez-Camblor P, Agustí A, et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med. 2009;180:3–10. https://doi.org/10.1164/rccm.200901-0047OC.CrossRefPubMed

Yang J, Antin P, Berx G, et al. Guidelines and definitions for research on epithelial–mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21:341–52. https://doi.org/10.1038/s41580-020-0237-9.CrossRefPubMedPubMedCentral

Mahmood MQ, Shukla SD, Ward C, Walters EH. The underappreciated role of epithelial mesenchymal transition in chronic obstructive pulmonary disease and its strong link to lung cancer. Biomolecules. 2021;11:1394. https://doi.org/10.3390/biom11091394.CrossRefPubMedPubMedCentral

Pain M, Bermudez O, Lacoste P, et al. Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype. Eur Respir Rev. 2014;23:118–30. https://doi.org/10.1183/09059180.00004413.CrossRefPubMed

10.

Szalontai K, Gémes N, Furák J, et al. Chronic obstructive pulmonary disease: epidemiology, biomarkers, and paving the way to lung cancer. J Clin Med. 2021;10:2889. https://doi.org/10.3390/jcm10132889.CrossRefPubMedPubMedCentral

11.

Lee H-W, Jose CC, Cuddapah S. Epithelial-mesenchymal transition: insights into nickel-induced lung diseases. Semin Cancer Biol. 2021;76:99–109. https://doi.org/10.1016/j.semcancer.2021.05.020.CrossRefPubMed

12.

Nowrin K, Sohal SS, Peterson G, et al. Epithelial-mesenchymal transition as a fundamental underlying pathogenic process in COPD airways: fibrosis, remodeling and cancer. Expert Rev Respir Med. 2014;8:547–59. https://doi.org/10.1586/17476348.2014.948853.CrossRefPubMed

13.

Vu T, Jin L, Datta PK. Effect of cigarette smoking on epithelial to mesenchymal transition (EMT) in lung cancer. J Clin Med. 2016;5:44. https://doi.org/10.3390/jcm5040044.CrossRefPubMedCentral

14.

Eapen MS, Sharma P, Thompson IE, et al. Heparin-binding epidermal growth factor (HB-EGF) drives EMT in patients with COPD: implications for disease pathogenesis and novel therapies. Lab Invest. 2019;99:150–7. https://doi.org/10.1038/s41374-018-0146-0.CrossRefPubMed

15.

Zhu L, Xu F, Kang X, et al. The antioxidant N-acetylcysteine promotes immune response and inhibits epithelial-mesenchymal transition to alleviate pulmonary fibrosis in chronic obstructive pulmonary disease by suppressing the VWF/p38 MAPK axis. Mol Med. 2021;27:97. https://doi.org/10.1186/s10020-021-00342-y.CrossRefPubMedPubMedCentral

16.

Mahmood MQ, Reid D, Ward C, et al. Transforming growth factor (TGF) β1 and Smad signalling pathways: a likely key to EMT-associated COPD pathogenesis. Respirology. 2017;22:133–40. https://doi.org/10.1111/resp.12882.CrossRefPubMed

17.

Mahmood MQ, Walters EH, Shukla SD, et al. β-catenin, Twist and Snail: transcriptional regulation of EMT in smokers and COPD, and relation to airflow obstruction. Sci Rep. 2017;7:10832. https://doi.org/10.1038/s41598-017-11375-x.CrossRefPubMedPubMedCentral

18.

Mahmood MQ, Ward C, Muller HK, et al. Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease. Med Oncol. 2017;34:45. https://doi.org/10.1007/s12032-017-0900-y.CrossRefPubMed

19.

Rodgman A, Smith CJ, Perfetti TA. The composition of cigarette smoke: a retrospective, with emphasis on polycyclic components. Hum Exp Toxicol. 2000;19:573–95. https://doi.org/10.1191/096032700701546514.CrossRefPubMed

20.

Horiyama S, Kunitomo M, Yoshikawa N, Nakamura K. Mass spectrometric approaches to the identification of potential ingredients in cigarette smoke causing cytotoxicity. Biol Pharm Bull. 2016;39:903–8. https://doi.org/10.1248/bpb.b16-00032.CrossRefPubMed

21.

Talikka M, Sierro N, Ivanov NV, et al. Genomic impact of cigarette smoke, with application to three smoking-related diseases. Crit Rev Toxicol. 2012;42:877–89. https://doi.org/10.3109/10408444.2012.725244.CrossRefPubMedPubMedCentral

22.

Soleimani F, Dobaradaran S, De-la-Torre GE, et al. Content of toxic components of cigarette, cigarette smoke vs cigarette butts: a comprehensive systematic review. Sci Total Environ. 2022;813:152667. https://doi.org/10.1016/j.scitotenv.2021.152667.CrossRefPubMed

23.

Aghapour M, Raee P, Moghaddam SJ, et al. Airway epithelial barrier dysfunction in chronic obstructive pulmonary disease: role of cigarette smoke exposure. Am J Respir Cell Mol Biol. 2018;58:157–69. https://doi.org/10.1165/rcmb.2017-0200TR.CrossRefPubMed

24.

Hecht SS, Hatsukami DK. Smokeless tobacco and cigarette smoking: chemical mechanisms and cancer prevention. Nat Rev Cancer. 2022;22:143–55. https://doi.org/10.1038/s41568-021-00423-4.CrossRefPubMed

25.

Benowitz NL, Liakoni E. Tobacco use disorder and cardiovascular health. Addiction. 2021. https://doi.org/10.1111/add.15703.CrossRefPubMedPubMedCentral

26.

Vareille M, Kieninger E, Edwards MR, Regamey N. The airway epithelium: soldier in the fight against respiratory viruses. Clin Microbiol Rev. 2011;24:210–29. https://doi.org/10.1128/CMR.00014-10.CrossRefPubMedPubMedCentral

27.

Nawroth JC, van der Does AM, Ryan Firth A, Kanso E. Multiscale mechanics of mucociliary clearance in the lung. Philos Trans R Soc Lond B Biol Sci. 2020;375:20190160. https://doi.org/10.1098/rstb.2019.0160.CrossRefPubMed

28.

Hikichi M, Mizumura K, Maruoka S, Gon Y. Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke. J Thorac Dis. 2019;11:S2129–40. https://doi.org/10.21037/jtd.2019.10.43.CrossRefPubMedPubMedCentral

29.

Ma Y, Long Y, Chen Y. Roles of inflammasome in cigarette smoke-related diseases and physiopathological disorders: mechanisms and therapeutic opportunities. Front Immunol. 2021;12:720049. https://doi.org/10.3389/fimmu.2021.720049.CrossRefPubMedPubMedCentral

30.

Brajer-Luftmann B, Nowicka A, Kaczmarek M, et al. Damage-associated molecular patterns and myeloid-derived suppressor cells in bronchoalveolar lavage fluid in chronic obstructive pulmonary disease patients. J Immunol Res. 2019;2019:9708769. https://doi.org/10.1155/2019/9708769.CrossRefPubMedPubMedCentral

31.

Kopa PN, Pawliczak R. Effect of smoking on gene expression profile—overall mechanism, impact on respiratory system function, and reference to electronic cigarettes. Toxicol Mech Methods. 2018;28:397–409. https://doi.org/10.1080/15376516.2018.1461289.CrossRefPubMed

32.

Hung RJ, Hall J, Brennan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol. 2005;162:925–42. https://doi.org/10.1093/aje/kwi318.CrossRefPubMed

33.

Rennard SI. Inflammation and repair processes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:S12-16. https://doi.org/10.1164/ajrccm.160.supplement_1.5.CrossRefPubMed

34.

Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138:16–27. https://doi.org/10.1016/j.jaci.2016.05.011.CrossRefPubMed

35.

McGuinness AJA, Sapey E. Oxidative stress in COPD: sources, markers, and potential mechanisms. J Clin Med. 2017;6:E21. https://doi.org/10.3390/jcm6020021.CrossRefPubMed

36.

Taniguchi A, Tsuge M, Miyahara N, Tsukahara H. Reactive oxygen species and antioxidative defense in chronic obstructive pulmonary disease. Antioxidants (Basel). 2021;10:1537. https://doi.org/10.3390/antiox10101537.CrossRef

37.

Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol. 2009;9:377–84. https://doi.org/10.1038/nri2530.CrossRefPubMed

38.

Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov. 2013;12:543–59. https://doi.org/10.1038/nrd4025.CrossRefPubMed

39.

Zuo L, He F, Sergakis GG, et al. Interrelated role of cigarette smoking, oxidative stress, and immune response in COPD and corresponding treatments. Am J Physiol Lung Cell Mol Physiol. 2014;307:L205-218. https://doi.org/10.1152/ajplung.00330.2013.CrossRefPubMed

40.

Nasri A, Foisset F, Ahmed E, et al. Roles of mesenchymal cells in the lung: from lung development to chronic obstructive pulmonary disease. Cells. 2021;10:3467. https://doi.org/10.3390/cells10123467.CrossRefPubMedPubMedCentral

41.

Shaykhiev R, Crystal RG. Early events in the pathogenesis of chronic obstructive pulmonary disease. Smoking-induced reprogramming of airway epithelial basal progenitor cells. Ann Am Thorac Soc. 2014;11 Suppl 5:S252-258. https://doi.org/10.1513/AnnalsATS.201402-049AW.CrossRefPubMed

42.

Yao R-Q, Ren C, Xia Z-F, Yao Y-M. Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles. Autophagy. 2021;17:385–401. https://doi.org/10.1080/15548627.2020.1725377.CrossRefPubMed

43.

Aghapour M, Remels AHV, Pouwels SD, et al. Mitochondria: at the crossroads of regulating lung epithelial cell function in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2020;318:L149–64. https://doi.org/10.1152/ajplung.00329.2019.CrossRefPubMed

44.

Kanithi M, Junapudi S, Shah SI, et al. Alterations of mitochondrial network by cigarette smoking and E-cigarette vaping. Cells. 2022;11:1688. https://doi.org/10.3390/cells11101688.CrossRefPubMedPubMedCentral

45.

Naiel S, Tat V, Padwal M, et al. Protein misfolding and endoplasmic reticulum stress in chronic lung disease: will cell-specific targeting be the key to the cure? Chest. 2020;157:1207–20. https://doi.org/10.1016/j.chest.2019.11.009.CrossRefPubMed

46.

Kelsen SG. The unfolded protein response in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016;13:S138–45. https://doi.org/10.1513/AnnalsATS.201506-320KV.CrossRefPubMedPubMedCentral

47.

Bradley KL, Stokes CA, Marciniak SJ, et al. Role of unfolded proteins in lung disease. Thorax. 2021;76:92–9. https://doi.org/10.1136/thoraxjnl-2019-213738.CrossRefPubMed

48.

Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:155–61. https://doi.org/10.1164/rccm.201201-0034OC.CrossRefPubMed

49.

de-Torres JP, Wilson DO, Sanchez-Salcedo P, et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD lung cancer screening score. Am J Respir Crit Care Med. 2015;191:285–91. https://doi.org/10.1164/rccm.201407-1210OC.CrossRefPubMedPubMedCentral

50.

Goffin JR, Pond GR, Puksa S, et al. Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population. BMC Pulm Med. 2020;20:300. https://doi.org/10.1186/s12890-020-01344-y.CrossRefPubMedPubMedCentral

51.

Ruparel M, Quaife SL, Dickson JL, et al. Prevalence, symptom burden, and underdiagnosis of chronic obstructive pulmonary disease in a lung cancer screening cohort. Ann Am Thorac Soc. 2020;17:869–78. https://doi.org/10.1513/AnnalsATS.201911-857OC.CrossRefPubMedPubMedCentral

52.

Zheng Y, Huang Y, Zheng X, et al. Deaths from COPD in patients with cancer: a population-based study. Aging. 2021;13:12641–59. https://doi.org/10.18632/aging.202939.CrossRefPubMedPubMedCentral

53.

Hopkins RJ, Duan F, Chiles C, et al. Reduced expiratory flow rate among heavy smokers increases lung cancer risk. Results from the National Lung Screening Trial-American College of Radiology Imaging Network Cohort. Ann Am Thorac Soc. 2017;14:392–402. https://doi.org/10.1513/AnnalsATS.201609-741OC.CrossRefPubMedPubMedCentral

54.

Punturieri A, Szabo E, Croxton TL, et al. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst. 2009;101:554–9. https://doi.org/10.1093/jnci/djp023.CrossRefPubMedPubMedCentral

55.

Vermaelen K, Brusselle G. Exposing a deadly alliance: novel insights into the biological links between COPD and lung cancer. Pulm Pharmacol Ther. 2013;26:544–54. https://doi.org/10.1016/j.pupt.2013.05.003.CrossRefPubMed

56.

Lee K, Cohn D, Liu Z, et al. Phenotypic and endotypic features of COPD associated with lung cancer development. JCO. 2022;40:e13563–e13563. https://doi.org/10.1200/JCO.2022.40.16_suppl.e13563.CrossRef

57.

Papi A, Casoni G, Caramori G, et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax. 2004;59:679–81. https://doi.org/10.1136/thx.2003.018291.CrossRefPubMedPubMedCentral

58.

Sohal SS, Mahmood MQ, Walters EH. Clinical significance of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD): potential target for prevention of airway fibrosis and lung cancer. Clin Transl Med. 2014;3:33. https://doi.org/10.1186/s40169-014-0033-2.CrossRefPubMedPubMedCentral

59.

Caramori G, Ruggeri P, Mumby S, et al. Molecular links between COPD and lung cancer: new targets for drug discovery? Expert Opin Ther Targets. 2019;23:539–53. https://doi.org/10.1080/14728222.2019.1615884.CrossRefPubMed

60.

Eapen MS, Hansbro PM, Larsson-Callerfelt A-K, et al. Chronic obstructive pulmonary disease and lung cancer: underlying pathophysiology and new therapeutic modalities. Drugs. 2018;78:1717–40. https://doi.org/10.1007/s40265-018-1001-8.CrossRefPubMed

61.

Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer. 2015;90:121–7. https://doi.org/10.1016/j.lungcan.2015.08.017.CrossRefPubMed

62.

Jolly MK, Ward C, Eapen MS, et al. Epithelial–mesenchymal transition, a spectrum of states: role in lung development, homeostasis, and disease. Dev Dyn. 2018;247:346–58. https://doi.org/10.1002/dvdy.24541.CrossRefPubMed

63.

Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69–84. https://doi.org/10.1038/s41580-018-0080-4.CrossRefPubMed

64.

Kim DH, Xing T, Yang Z, et al. Epithelial mesenchymal transition in embryonic development, tissue repair and cancer: a comprehensive overview. J Clin Med. 2017;7:1. https://doi.org/10.3390/jcm7010001.CrossRefPubMedCentral

65.

Knight DA, Grainge CL, Stick SM, et al. Epithelial mesenchymal transition in respiratory disease: fact or fiction. Chest. 2020;157:1591–6. https://doi.org/10.1016/j.chest.2019.12.014.CrossRefPubMed

66.

Carlier FM, Dupasquier S, Ambroise J, et al. Canonical WNT pathway is activated in the airway epithelium in chronic obstructive pulmonary disease. EBioMedicine. 2020;61:103034. https://doi.org/10.1016/j.ebiom.2020.103034.CrossRefPubMedPubMedCentral

67.

Mahmood MQ, Sohal SS, Shukla SD, et al. Epithelial mesenchymal transition in smokers: large versus small airways and relation to airflow obstruction. Int J Chron Obstruct Pulmon Dis. 2015;10:1515–24. https://doi.org/10.2147/COPD.S81032.CrossRefPubMedPubMedCentral

68.

Milara J, Peiró T, Serrano A, Cortijo J. Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke. Thorax. 2013;68:410–20. https://doi.org/10.1136/thoraxjnl-2012-201761.CrossRefPubMed

69.

Sohal SS, Reid D, Soltani A, et al. Reticular basement membrane fragmentation and potential epithelial mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease. Respirology. 2010;15:930–8. https://doi.org/10.1111/j.1440-1843.2010.01808.x.CrossRefPubMed

70.

Courtney J-M, Spafford PL. The role of epithelial–mesenchymal transition in chronic obstructive pulmonary disease. Cells Tissues Organs. 2017;203:99–104. https://doi.org/10.1159/000450919.CrossRefPubMed

71.

Koczulla A-R, Jonigk D, Wolf T, et al. Krüppel-like zinc finger proteins in end-stage COPD lungs with and without severe alpha1-antitrypsin deficiency. Orphanet J Rare Dis. 2012;7:29. https://doi.org/10.1186/1750-1172-7-29.CrossRefPubMedPubMedCentral

72.

Wong SHM, Fang CM, Chuah L-H, et al. E-cadherin: its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 2018;121:11–22. https://doi.org/10.1016/j.critrevonc.2017.11.010.CrossRefPubMed

73.

Loh C-Y, Chai JY, Tang TF, et al. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8:E1118. https://doi.org/10.3390/cells8101118.CrossRefPubMed

74.

Gohy ST, Hupin C, Fregimilicka C, et al. Imprinting of the COPD airway epithelium for dedifferentiation and mesenchymal transition. Eur Respir J. 2015;45:1258–72. https://doi.org/10.1183/09031936.00135814.CrossRefPubMed

75.

Zhu J, Wang F, Feng X, et al. Family with sequence similarity 13 member A mediates TGF-β1-induced EMT in small airway epithelium of patients with chronic obstructive pulmonary disease. Respir Res. 2021;22:192. https://doi.org/10.1186/s12931-021-01783-z.CrossRefPubMedPubMedCentral

76.

Ye R, Wang C, Sun P, et al. AGR3 regulates airway epithelial junctions in patients with frequent exacerbations of COPD. Front Pharmacol. 2021;12:669403. https://doi.org/10.3389/fphar.2021.669403.CrossRefPubMedPubMedCentral

77.

Xu F, Liu X-C, Li L, et al. Effects of TRPC1 on epithelial mesenchymal transition in human airway in chronic obstructive pulmonary disease. Medicine (Baltimore). 2017;96:e8166. https://doi.org/10.1097/MD.0000000000008166.CrossRef

78.

Zheng L, Jiang Y-L, Fei J, et al. Circulatory cadmium positively correlates with epithelial-mesenchymal transition in patients with chronic obstructive pulmonary disease. Ecotoxicol Environ Saf. 2021;215:112164. https://doi.org/10.1016/j.ecoenv.2021.112164.CrossRefPubMed

79.

Shirahata T, Nakamura H, Nakajima T, et al. Plasma sE-cadherin and the plasma sE-cadherin/sVE-cadherin ratio are potential biomarkers for chronic obstructive pulmonary disease. Biomarkers. 2018;23:414–21. https://doi.org/10.1080/1354750X.2018.1434682.CrossRefPubMed

80.

Li Z, Li Y, Liu S, Qin Z. Extracellular S100A4 as a key player in fibrotic diseases. J Cell Mol Med. 2020;24:5973–83. https://doi.org/10.1111/jcmm.15259.CrossRefPubMedPubMedCentral

81.

Qin H-Y, Li M-D, Xie G-F, et al. Associations among S100A4, Sphingosine-1-phosphate, and pulmonary function in patients with chronic obstructive pulmonary disease. Oxid Med Cell Longev. 2022;2022:6041471. https://doi.org/10.1155/2022/6041471.CrossRefPubMedPubMedCentral

82.

Sohal SS, Reid D, Soltani A, et al. Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary disease. Respir Res. 2011;12:130. https://doi.org/10.1186/1465-9921-12-130.CrossRefPubMedPubMedCentral

83.

Usman S, Waseem NH, Nguyen TKN, et al. Vimentin is at the heart of epithelial mesenchymal transition (EMT) mediated metastasis. Cancers (Basel). 2021;13:4985. https://doi.org/10.3390/cancers13194985.CrossRef

84.

Nomura T, Huang W-C, Zhau HE, et al. β2-Microglobulin-mediated signaling as a target for cancer therapy. Anticancer Agents Med Chem. 2014;14:343–52. https://doi.org/10.2174/18715206113139990092.CrossRefPubMedPubMedCentral

85.

Josson S, Nomura T, Lin J-T, et al. β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res. 2011;71:2600–10. https://doi.org/10.1158/0008-5472.CAN-10-3382.CrossRefPubMedPubMedCentral

86.

Zhang A, Wang B, Yang M, et al. β2-microglobulin induces epithelial-mesenchymal transition in human renal proximal tubule epithelial cells in vitro. BMC Nephrol. 2015;16:60. https://doi.org/10.1186/s12882-015-0057-x.CrossRefPubMedPubMedCentral

87.

Wang J, Yang W, Wang T, et al. Mesenchymal stromal cells-derived β2-microglobulin promotes epithelial-mesenchymal transition of esophageal squamous cell carcinoma cells. Sci Rep. 2018;8:5422. https://doi.org/10.1038/s41598-018-23651-5.CrossRefPubMedPubMedCentral

88.

Gao N, Wang Y, Zheng C-M, et al. β2-Microglobulin participates in development of lung emphysema by inducing lung epithelial cell senescence. Am J Physiol Lung Cell Mol Physiol. 2017;312:L669–77. https://doi.org/10.1152/ajplung.00516.2016.CrossRefPubMedPubMedCentral

89.

Wu Z, Yan M, Zhang M, et al. β2-microglobulin as a biomarker of pulmonary fibrosis development in COPD patients. Aging (Albany NY). 2020;13:1251–63. https://doi.org/10.18632/aging.202266.CrossRef

90.

Zheng X, Li W, Ren L, et al. The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: potential target for anticancer therapy. Pharmacol Ther. 2019;195:85–99. https://doi.org/10.1016/j.pharmthera.2018.10.011.CrossRefPubMed

91.

Riemma MA, Cerqua I, Romano B, et al. Sphingosine-1-phosphate/TGF-β axis drives epithelial mesenchymal transition in asthma-like disease. Br J Pharmacol. 2022;179:1753–68. https://doi.org/10.1111/bph.15754.CrossRefPubMed

92.

Milara J, Navarro R, Juan G, et al. Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition. Thorax. 2012;67:147–56. https://doi.org/10.1136/thoraxjnl-2011-200026.CrossRefPubMed

93.

De Cunto G, Brancaleone V, Riemma MA, et al. Functional contribution of sphingosine-1-phosphate to airway pathology in cigarette smoke-exposed mice. Br J Pharmacol. 2020;177:267–81. https://doi.org/10.1111/bph.14861.CrossRefPubMed

94.

Sharma P, Nag A. CUL4A ubiquitin ligase: a promising drug target for cancer and other human diseases. Open Biol. 2014;4:130217. https://doi.org/10.1098/rsob.130217.CrossRefPubMedPubMedCentral

95.

Wang Y, Wen M, Kwon Y, et al. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014;74:520–31. https://doi.org/10.1158/0008-5472.CAN-13-2182.CrossRefPubMed

96.

Cao P-P, Chen W-J, Pang H-L, et al. Effect of CUL4A on the metastatic potential of lung adenocarcinoma to the bone. Oncol Rep. 2020;43:662–70. https://doi.org/10.3892/or.2019.7448.CrossRefPubMed

97.

Ren Y, Zhang Y, Fan L, et al. The cullin4A is up-regulated in chronic obstructive pulmonary disease patient and contributes to epithelial-mesenchymal transition in small airway epithelium. Respir Res. 2019. https://doi.org/10.1186/s12931-019-1048-4.CrossRefPubMedPubMedCentral

98.

Aschner Y, Downey GP. Transforming growth factor-β: master regulator of the respiratory system in health and disease. Am J Respir Cell Mol Biol. 2016;54:647–55. https://doi.org/10.1165/rcmb.2015-0391TR.CrossRefPubMedPubMedCentral

99.

Ahmadi A, Najafi M, Farhood B, Mortezaee K. Transforming growth factor-β signaling: tumorigenesis and targeting for cancer therapy. J Cell Physiol. 2019;234:12173–87. https://doi.org/10.1002/jcp.27955.CrossRefPubMed

100.

Zhang YE. Non-Smad pathways in TGF-β signaling. Cell Res. 2009;19:128–39. https://doi.org/10.1038/cr.2008.328.CrossRefPubMed

101.

Katsuno Y, Derynck R. Epithelial plasticity, epithelial–mesenchymal transition, and the TGF-β family. Dev Cell. 2021;56:726–46. https://doi.org/10.1016/j.devcel.2021.02.028.CrossRefPubMed

102.

Kahata K, Dadras MS, Moustakas A. TGF-β family signaling in epithelial differentiation and epithelial-mesenchymal transition. Cold Spring Harb Perspect Biol. 2018;10:a022194. https://doi.org/10.1101/cshperspect.a022194.CrossRefPubMedPubMedCentral

103.

Kasai H, Allen JT, Mason RM, et al. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res. 2005;6:56. https://doi.org/10.1186/1465-9921-6-56.CrossRefPubMedPubMedCentral

104.

Hackett T-L, Warner SM, Stefanowicz D, et al. Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-beta1. Am J Respir Crit Care Med. 2009;180:122–33. https://doi.org/10.1164/rccm.200811-1730OC.CrossRefPubMed

105.

Xie L, Zhou D, Xiong J, et al. Paraquat induce pulmonary epithelial-mesenchymal transition through transforming growth factor-β1-dependent mechanism. Exp Toxicol Pathol. 2016;68:69–76. https://doi.org/10.1016/j.etp.2015.09.010.CrossRefPubMed

106.

Soltani A, Sohal SS, Reid D, et al. Vessel-associated transforming growth factor-beta1 (TGF-β1) is increased in the bronchial reticular basement membrane in COPD and normal smokers. PLoS ONE. 2012;7:e39736. https://doi.org/10.1371/journal.pone.0039736.CrossRefPubMedPubMedCentral

107.

Shen H, Sun Y, Zhang S, et al. Cigarette smoke-induced alveolar epithelial-mesenchymal transition is mediated by Rac1 activation. Biochim Biophys Acta. 2014;1840:1838–49. https://doi.org/10.1016/j.bbagen.2014.01.033.CrossRefPubMed

108.

Guan S, Xu W, Han F, et al. Ginsenoside Rg1 attenuates cigarette smoke-induced pulmonary epithelial-mesenchymal transition via inhibition of the TGF-β1/Smad pathway. Biomed Res Int. 2017;2017:7171404. https://doi.org/10.1155/2017/7171404.CrossRefPubMedPubMedCentral

109.

Lin L, Hou G, Han D, et al. Ursolic acid alleviates airway-vessel remodeling and muscle consumption in cigarette smoke-induced emphysema rats. BMC Pulm Med. 2019;19:103. https://doi.org/10.1186/s12890-019-0826-6.CrossRefPubMedPubMedCentral

110.

Wu N, Wu Z, Sun J, et al. Small airway remodeling in diabetic and smoking chronic obstructive pulmonary disease patients. Aging (Albany NY). 2020;12:7927–44. https://doi.org/10.18632/aging.103112.CrossRef

111.

Pan K, Lu J, Song Y. Artesunate ameliorates cigarette smoke-induced airway remodelling via PPAR-γ/TGF-β1/Smad2/3 signalling pathway. Respir Res. 2021;22:91. https://doi.org/10.1186/s12931-021-01687-y.CrossRefPubMedPubMedCentral

112.

Huang P, Yan R, Zhang X, et al. Activating Wnt/β-catenin signaling pathway for disease therapy: challenges and opportunities. Pharmacol Ther. 2019;196:79–90. https://doi.org/10.1016/j.pharmthera.2018.11.008.CrossRefPubMed

113.

Gonzalez DM, Medici D. Signaling mechanisms of the epithelial–mesenchymal transition. Sci Signal. 2014;7:re8. https://doi.org/10.1126/scisignal.2005189.CrossRefPubMedPubMedCentral

114.

Wang Z, Li Z, Ji H. Direct targeting of β-catenin in the Wnt signaling pathway: current progress and perspectives. Med Res Rev. 2021;41:2109–29. https://doi.org/10.1002/med.21787.CrossRefPubMedPubMedCentral

115.

Eapen MS, Sohal SS. WNT/β-catenin pathway: a novel therapeutic target for attenuating airway remodelling and EMT in COPD. EBioMedicine. 2020;62:103095. https://doi.org/10.1016/j.ebiom.2020.103095.CrossRefPubMedPubMedCentral

116.

Zou W, Zou Y, Zhao Z, et al. Nicotine-induced epithelial-mesenchymal transition via Wnt/β-catenin signaling in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2013;304:L199–209. https://doi.org/10.1152/ajplung.00094.2012.CrossRefPubMed

117.

Su X, Chen J, Lin X, et al. FERMT3 mediates cigarette smoke-induced epithelial–mesenchymal transition through Wnt/β-catenin signaling. Respir Res. 2021;22:286. https://doi.org/10.1186/s12931-021-01881-y.CrossRefPubMedPubMedCentral

118.

Deng S, Leong HC, Datta A, et al. PI3K/AKT signaling tips the balance of cytoskeletal forces for cancer progression. Cancers (Basel). 2022;14:1652. https://doi.org/10.3390/cancers14071652.CrossRef

119.

Kotelevets L, Chastre E. Rac1 signaling: from intestinal homeostasis to colorectal cancer metastasis. Cancers (Basel). 2020;12:E665. https://doi.org/10.3390/cancers12030665.CrossRef

120.

Jiang J-X, Zhang S-J, Shen H-J, et al. Rac1 signaling regulates cigarette smoke-induced inflammation in the lung via the Erk1/2 MAPK and STAT3 pathways. Biochim Biophys Acta Mol Basis Dis. 2017;1863:1778–88. https://doi.org/10.1016/j.bbadis.2017.04.013.CrossRefPubMed

121.

Milara J, Peiró T, Serrano A, et al. Simvastatin increases the ability of roflumilast N-oxide to inhibit cigarette smoke-induced epithelial to mesenchymal transition in well-differentiated human bronchial epithelial cells in vitro. COPD. 2015;12:320–31. https://doi.org/10.3109/15412555.2014.948995.CrossRefPubMed

122.

Cho HJ, Baek KE, Saika S, et al. Snail is required for transforming growth factor-beta-induced epithelial–mesenchymal transition by activating PI3 kinase/Akt signal pathway. Biochem Biophys Res Commun. 2007;353:337–43. https://doi.org/10.1016/j.bbrc.2006.12.035.CrossRefPubMed

123.

Gui T, Sun Y, Shimokado A, Muragaki Y. The roles of mitogen-activated protein kinase pathways in TGF-β-induced epithelial-mesenchymal transition. J Signal Transduct. 2012;2012:289243. https://doi.org/10.1155/2012/289243.CrossRefPubMedPubMedCentral

124.

Li NY, Weber CE, Wai PY, et al. An MAPK-dependent pathway induces epithelial-mesenchymal transition via Twist activation in human breast cancer cell lines. Surgery. 2013;154:404–10. https://doi.org/10.1016/j.surg.2013.05.012.CrossRefPubMed

125.

Weichhart T, Säemann MD. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann Rheum Dis. 2008;67(Suppl 3):iii70-74. https://doi.org/10.1136/ard.2008.098459.CrossRefPubMed

126.

Jiang B, Guan Y, Shen H-J, et al. Akt/PKB signaling regulates cigarette smoke-induced pulmonary epithelial-mesenchymal transition. Lung Cancer. 2018;122:44–53. https://doi.org/10.1016/j.lungcan.2018.05.019.CrossRefPubMed

127.

Zinatizadeh MR, Schock B, Chalbatani GM, et al. The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases. Genes Dis. 2021;8:287–97. https://doi.org/10.1016/j.gendis.2020.06.005.CrossRefPubMed

128.

Markopoulos GS, Roupakia E, Marcu KB, Kolettas E. Epigenetic regulation of inflammatory cytokine-induced epithelial-to-mesenchymal cell transition and cancer stem cell generation. Cells. 2019;8:E1143. https://doi.org/10.3390/cells8101143.CrossRefPubMed

129.

Budovsky A, Fraifeld VE, Aronov S. Linking cell polarity, aging and rejuvenation. Biogerontology. 2011;12:167–75. https://doi.org/10.1007/s10522-010-9305-4.CrossRefPubMed

130.

Zhao Y, Xu Y, Li Y, et al. NF-κB-mediated inflammation leading to EMT via miR-200c is involved in cell transformation induced by cigarette smoke extract. Toxicol Sci. 2013;135:265–76. https://doi.org/10.1093/toxsci/kft150.CrossRefPubMed

131.

Lu L, Xu H, Yang P, et al. Involvement of HIF-1α-regulated miR-21, acting via the Akt/NF-κB pathway, in malignant transformation of HBE cells induced by cigarette smoke extract. Toxicol Lett. 2018;289:14–21. https://doi.org/10.1016/j.toxlet.2018.02.027.CrossRefPubMed

132.

Ma L, Jiang M, Zhao X, et al. Cigarette and IL-17A synergistically induce bronchial epithelial-mesenchymal transition via activating IL-17R/NF-κB signaling. BMC Pulm Med. 2020;20:26. https://doi.org/10.1186/s12890-020-1057-6.CrossRefPubMedPubMedCentral

133.

Zhou H, Liu Y, Wang Z, et al. CD147 promoted epithelial mesenchymal transition in airway epithelial cells induced by cigarette smoke via oxidative stress signaling pathway. COPD. 2020;17:269–79. https://doi.org/10.1080/15412555.2020.1758051.CrossRefPubMed

134.

Chang C-J, Lin C-F, Chen B-C, et al. SHP2: The protein tyrosine phosphatase involved in chronic pulmonary inflammation and fibrosis. IUBMB Life. 2022;74:131–42. https://doi.org/10.1002/iub.2559.CrossRefPubMed

135.

Li F-F, Shen J, Shen H-J, et al. Shp2 plays an important role in acute cigarette smoke-mediated lung inflammation. J Immunol. 2012;189:3159–67. https://doi.org/10.4049/jimmunol.1200197.CrossRefPubMedPubMedCentral

136.

Liu Y-N, Guan Y, Shen J, et al. Shp2 positively regulates cigarette smoke-induced epithelial mesenchymal transition by mediating MMP-9 production. Respir Res. 2020;21:161. https://doi.org/10.1186/s12931-020-01426-9.CrossRefPubMedPubMedCentral

137.

Whitaker RH, Cook JG. Stress relief techniques: p38 MAPK determines the balance of cell cycle and apoptosis pathways. Biomolecules. 2021;11:1444. https://doi.org/10.3390/biom11101444.CrossRefPubMedPubMedCentral

138.

Jiang Z, Zhang Y, Zhu Y, et al. Cathelicidin induces epithelial-mesenchymal transition to promote airway remodeling in smoking-related chronic obstructive pulmonary disease. Ann Transl Med. 2021;9:223. https://doi.org/10.21037/atm-20-2196.CrossRefPubMedPubMedCentral

139.

Babaei G, Aliarab A, Asghari Vostakolaei M, et al. Crosslink between p53 and metastasis: focus on epithelial-mesenchymal transition, cancer stem cell, angiogenesis, autophagy, and anoikis. Mol Biol Rep. 2021;48:7545–57. https://doi.org/10.1007/s11033-021-06706-1.CrossRefPubMed

140.

Wang W, Xiao L, Pan D, Hu L. ASF1B enhances migration and invasion of lung cancers cell via regulating the P53-mediated epithelial-mesenchymal transformation (EMT) signaling pathway. Neoplasma. 2022;69:361–9. https://doi.org/10.4149/neo_2021_210818N1181.CrossRefPubMed

141.

Liu X, Wang Z, Yang Q, et al. RNA demethylase ALKBH5 prevents lung cancer progression by regulating EMT and stemness via regulating p53. Front Oncol. 2022;12:858694. https://doi.org/10.3389/fonc.2022.858694.CrossRefPubMedPubMedCentral

142.

Kawami M, Takenaka S, Akai M, et al. Characterization of miR-34a-induced epithelial-mesenchymal transition in non-small lung cancer cells focusing on p53. Biomolecules. 2021;11:1853. https://doi.org/10.3390/biom11121853.CrossRefPubMedPubMedCentral

143.

Jung S, Kim DH, Choi YJ, et al. Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Sci Rep. 2021;11:19667. https://doi.org/10.1038/s41598-021-99267-z.CrossRefPubMedPubMedCentral

144.

Smith LE, Denissenko MF, Bennett WP, et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst. 2000;92:803–11. https://doi.org/10.1093/jnci/92.10.803.CrossRefPubMed

145.

Bein K, Leikauf GD. Acrolein—a pulmonary hazard. Mol Nutr Food Res. 2011;55:1342–60. https://doi.org/10.1002/mnfr.201100279.CrossRefPubMed

146.

Le Calvez F, Mukeria A, Hunt JD, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 2005;65:5076–83. https://doi.org/10.1158/0008-5472.CAN-05-0551.CrossRefPubMed

147.

Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat. 2003;21:229–39. https://doi.org/10.1002/humu.10177.CrossRefPubMed

148.

Sun X, Shang J, Wu A, et al. Identification of dynamic signatures associated with smoking-related squamous cell lung cancer and chronic obstructive pulmonary disease. J Cell Mol Med. 2020;24:1614–25. https://doi.org/10.1111/jcmm.14852.CrossRefPubMed

149.

Mizuno S, Ishizaki T, Kadowaki M, et al. p53 signaling pathway polymorphisms associated with emphysematous changes in patients with COPD. Chest. 2017;152:58–69. https://doi.org/10.1016/j.chest.2017.03.012.CrossRefPubMed

150.

Arif E, Vibhuti A, Deepak D, et al. COX2 and p53 risk-alleles coexist in COPD. Clin Chim Acta. 2008;397:48–50. https://doi.org/10.1016/j.cca.2008.07.010.CrossRefPubMed

151.

Siganaki M, Koutsopoulos AV, Neofytou E, et al. Deregulation of apoptosis mediators’ p53 and bcl2 in lung tissue of COPD patients. Respir Res. 2010;11:46. https://doi.org/10.1186/1465-9921-11-46.CrossRefPubMedPubMedCentral

152.

Sohal SS, Soltani A, Reid D, et al. A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial-mesenchymal transition (EMT) in large airway samples in COPD: an exploratory proof of concept study. Int J Chron Obstruct Pulmon Dis. 2014;9:533–42. https://doi.org/10.2147/COPD.S63911.CrossRefPubMedPubMedCentral

153.

Raymakers AJN, Sadatsafavi M, Sin DD, et al. Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study. Eur Respir J. 2019;53:1801257. https://doi.org/10.1183/13993003.01257-2018.CrossRefPubMed

154.

Kiri VA, Fabbri LM, Davis KJ, Soriano JB. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir Med. 2009;103:85–90. https://doi.org/10.1016/j.rmed.2008.07.024.CrossRefPubMed

155.

Parimon T, Chien JW, Bryson CL, et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:712–9. https://doi.org/10.1164/rccm.200608-1125OC.CrossRefPubMed

156.

Ge F, Feng Y, Huo Z, et al. Inhaled corticosteroids and risk of lung cancer among chronic obstructive pulmonary disease patients: a comprehensive analysis of nine prospective cohorts. Transl Lung Cancer Res. 2021;10:1266–76. https://doi.org/10.21037/tlcr-20-1126.CrossRefPubMedPubMedCentral

157.

Zheng J-P, Wen F-Q, Bai C-X, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2:187–94. https://doi.org/10.1016/S2213-2600(13)70286-8.CrossRefPubMed

158.

Barnes PJ. Oxidative stress-based therapeutics in COPD. Redox Biol. 2020;33:101544. https://doi.org/10.1016/j.redox.2020.101544.CrossRefPubMedPubMedCentral

159.

Rennard SI, Calverley PMA, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast–the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18. https://doi.org/10.1186/1465-9921-12-18.CrossRefPubMedPubMedCentral

160.

Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163:53–67. https://doi.org/10.1111/j.1476-5381.2011.01218.x.CrossRefPubMedPubMedCentral

161.

Cortijo J, Iranzo A, Milara X, et al. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury. Br J Pharmacol. 2009;156:534–44. https://doi.org/10.1111/j.1476-5381.2008.00041.x.CrossRefPubMedPubMedCentral

162.

Martorana PA, Beume R, Lucattelli M, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med. 2005;172:848–53. https://doi.org/10.1164/rccm.200411-1549OC.CrossRefPubMed

163.

Milara J, Peiró T, Serrano A, et al. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD. Pulm Pharmacol Ther. 2014;28:138–48. https://doi.org/10.1016/j.pupt.2014.02.001.CrossRefPubMed

164.

Cardwell CR, Mc Menamin Ú, Hughes CM, Murray LJ. Statin use and survival from lung cancer: a population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2015;24:833–41. https://doi.org/10.1158/1055-9965.EPI-15-0052.CrossRefPubMed

165.

Lin JJ, Ezer N, Sigel K, et al. The effect of statins on survival in patients with stage IV lung cancer. Lung Cancer. 2016;99:137–42. https://doi.org/10.1016/j.lungcan.2016.07.006.CrossRefPubMed

166.

Ms H, Ic C, Cp L, et al. Statin improves survival in patients with EGFR-TKI lung cancer: a nationwide population-based study. PLoS ONE. 2017;12:e0171137. https://doi.org/10.1371/journal.pone.0171137.CrossRef

167.

Seckl MJ, Ottensmeier CH, Cullen M, et al. Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR). J Clin Oncol. 2017;35:1506–14. https://doi.org/10.1200/JCO.2016.69.7391.CrossRefPubMedPubMedCentral

168.

Lee Y, Lee KH, Lee GK, et al. Randomized phase II study of afatinib plus simvastatin versus afatinib alone in previously treated patients with advanced nonadenocarcinomatous non-small cell lung cancer. Cancer Res Treat. 2017;49:1001–11. https://doi.org/10.4143/crt.2016.546.CrossRefPubMedPubMedCentral

169.

Nishikawa S, Menju T, Takahashi K, et al. Statins may have double-edged effects in patients with lung adenocarcinoma after lung resection. Cancer Manag Res. 2019;11:3419–32. https://doi.org/10.2147/CMAR.S200819.CrossRefPubMedPubMedCentral

170.

Raymakers A, Sin DD, Sadatsafavi M, et al. Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study. Respir Res. 2020;21:118. https://doi.org/10.1186/s12931-020-01344-w.CrossRefPubMedPubMedCentral

171.

Liu J-C, Yang T-Y, Hsu Y-P, et al. Statins dose-dependently exert a chemopreventive effect against lung cancer in COPD patients: a population-based cohort study. Oncotarget. 2016;7:59618–29. https://doi.org/10.18632/oncotarget.11162.CrossRefPubMedPubMedCentral

172.

Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications. Front Oncol. 2018;8:24. https://doi.org/10.3389/fonc.2018.00024.CrossRefPubMedPubMedCentral

173.

Zhang Y, Xiao W, Jiang Y, et al. Levels of components of the urokinase-type plasminogen activator system are related to chronic obstructive pulmonary disease parenchymal destruction and airway remodelling. J Int Med Res. 2012;40:976–85. https://doi.org/10.1177/147323001204000316.CrossRefPubMed

174.

Wang Q, Wang Y, Zhang Y, et al. Involvement of urokinase in cigarette smoke extract-induced epithelial-mesenchymal transition in human small airway epithelial cells. Lab Invest. 2015;95:469–79. https://doi.org/10.1038/labinvest.2015.33.CrossRefPubMed

175.

Wang Q, Wang Y, Zhang Y, et al. The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease. Respir Res. 2013;14:67. https://doi.org/10.1186/1465-9921-14-67.CrossRefPubMedPubMedCentral

176.

Schweitzer KS, Johnstone BH, Garrison J, et al. Adipose stem cell treatment in mice attenuates lung and systemic injury induced by cigarette smoking. Am J Respir Crit Care Med. 2011;183:215–25. https://doi.org/10.1164/rccm.201001-0126OC.CrossRefPubMed

177.

Li X, Michaeloudes C, Zhang Y, et al. Mesenchymal stem cells alleviate oxidative stress-induced mitochondrial dysfunction in the airways. J Allergy Clin Immunol. 2018;141:1634-1645.e5. https://doi.org/10.1016/j.jaci.2017.08.017.CrossRefPubMed

178.

Chen T-Y, Liu C-H, Chen T-H, et al. Conditioned media of adipose-derived stem cells suppresses sidestream cigarette smoke extract induced cell death and epithelial–mesenchymal transition in lung epithelial cells. Int J Mol Sci. 2021;22:12069. https://doi.org/10.3390/ijms222112069.CrossRefPubMedPubMedCentral

179.

Gao Y, Chu S, Zhang Z, Chen N. Hepataprotective effects of ginsenoside Rg1—a review. J Ethnopharmacol. 2017;206:178–83. https://doi.org/10.1016/j.jep.2017.04.012.CrossRefPubMed

180.

Huang Z, Zhang Z, Zhou C, et al. Epithelial–mesenchymal transition: the history, regulatory mechanism, and cancer therapeutic opportunities. MedComm. 2022;3:e144. https://doi.org/10.1002/mco2.144.CrossRefPubMedPubMedCentral

181.

Herbertz S, Sawyer JS, Stauber AJ, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Dev Ther. 2015;9:4479–99. https://doi.org/10.2147/DDDT.S86621.CrossRef

182.

Gunderson CC, Walker JL, Mannel RS, et al. A phase IB trial of paclitaxel and carboplatin + galunisertib in patients with uterine and ovarian carcinosarcoma. Gynecol Oncol. 2020;159:23. https://doi.org/10.1016/j.ygyno.2020.06.048.CrossRef

183.

Gueorguieva I, Tabernero J, Melisi D, et al. Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer. Cancer Chemother Pharmacol. 2019;84:1003–15. https://doi.org/10.1007/s00280-019-03931-1.CrossRefPubMed

184.

Giannelli G, Santoro A, Kelley RK, et al. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. PLoS ONE. 2020;15:e0222259. https://doi.org/10.1371/journal.pone.0222259.CrossRefPubMedPubMedCentral

185.

Paller C, Pu H, Begemann DE, et al. TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer. Prostate. 2019;79:31–43. https://doi.org/10.1002/pros.23708.CrossRefPubMed

186.

Chiang S-L, Velmurugan BK, Chung C-M, et al. Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma. Sci Rep. 2017;7:6235. https://doi.org/10.1038/s41598-017-06673-3.CrossRefPubMedPubMedCentral

187.

Liu X, Wu Y, Zhou Z, et al. Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis. Int J Mol Med. 2019;44:683–93. https://doi.org/10.3892/ijmm.2019.4241.CrossRefPubMedPubMedCentral

188.

Watanabe Y, Imanishi Y, Ozawa H, et al. Selective EP2 and Cox-2 inhibition suppresses cell migration by reversing epithelial-to-mesenchymal transition and Cox-2 overexpression and E-cadherin downregulation are implicated in neck metastasis of hypopharyngeal cancer. Am J Transl Res. 2020;12:1096–113.PubMedPubMedCentral

189.

Xiong S, Huang W, Liu X, et al. Celecoxib synergistically enhances MLN4924-induced cytotoxicity and EMT inhibition via AKT and ERK pathways in human urothelial carcinoma. Cell Transplant. 2022;31:9636897221077920. https://doi.org/10.1177/09636897221077921.CrossRef

190.

Zaman A, Bivona TG. Targeting AXL in NSCLC. Lung Cancer (Auckl). 2021;12:67–79. https://doi.org/10.2147/LCTT.S305484.CrossRef

191.

Namba K, Shien K, Takahashi Y, et al. Activation of AXL as a preclinical acquired resistance mechanism against osimertinib treatment in EGFR-mutant non-small cell lung cancer cells. Mol Cancer Res. 2019;17:499–507. https://doi.org/10.1158/1541-7786.MCR-18-0628.CrossRefPubMed

192.

Zhou L, Liu X-D, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35:2687–97. https://doi.org/10.1038/onc.2015.343.CrossRefPubMed

193.

Chlapek P, Slavikova V, Mazanek P, et al. Why differentiation therapy sometimes fails: molecular mechanisms of resistance to retinoids. Int J Mol Sci. 2018;19:E132. https://doi.org/10.3390/ijms19010132.CrossRefPubMed

194.

Liang C, Qiao G, Liu Y, et al. Overview of all-trans-retinoic acid (ATRA) and its analogues: structures, activities, and mechanisms in acute promyelocytic leukaemia. Eur J Med Chem. 2021;220:113451. https://doi.org/10.1016/j.ejmech.2021.113451.CrossRefPubMed

195.

Bobal P, Lastovickova M, Bobalova J. The role of ATRA, natural ligand of retinoic acid receptors, on EMT-related proteins in breast cancer: minireview. Int J Mol Sci. 2021;22:13345. https://doi.org/10.3390/ijms222413345.CrossRefPubMedPubMedCentral

196.

Zanetti A, Affatato R, Centritto F, et al. All-trans-retinoic acid modulates the plasticity and inhibits the motility of breast cancer cells: ROLE OF NOTCH1 AND TRANSFORMING GROWTH FACTOR (TGFβ). J Biol Chem. 2015;290:17690–709. https://doi.org/10.1074/jbc.M115.638510.CrossRefPubMedPubMedCentral

197.

Cui J, Gong M, Fang S, et al. All-trans retinoic acid reverses malignant biological behavior of hepatocarcinoma cells by regulating miR-200 family members. Genes Dis. 2021;8:509–20. https://doi.org/10.1016/j.gendis.2019.12.012.CrossRefPubMed

198.

Blaschuk OW. Potential therapeutic applications of N-cadherin antagonists and agonists. Front Cell Dev Biol. 2022;10:866200. https://doi.org/10.3389/fcell.2022.866200.CrossRefPubMedPubMedCentral

199.

Augustine CK, Yoshimoto Y, Gupta M, et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res. 2008;68:3777–84. https://doi.org/10.1158/0008-5472.CAN-07-5949.CrossRefPubMed

200.

Inui N, Sakai S, Kitagawa M. Molecular pathogenesis of pulmonary fibrosis, with focus on pathways related to TGF-β and the ubiquitin-proteasome pathway. Int J Mol Sci. 2021;22:6107. https://doi.org/10.3390/ijms22116107.CrossRefPubMedPubMedCentral

201.

Skibba M, Drelich A, Poellmann M, et al. Nanoapproaches to modifying epigenetics of epithelial mesenchymal transition for treatment of pulmonary fibrosis. Front Pharmacol. 2020;11:607689. https://doi.org/10.3389/fphar.2020.607689.CrossRefPubMedPubMedCentral

202.

Lv Q, Wang J, Xu C, et al. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways. Mol Med. 2020;26:49. https://doi.org/10.1186/s10020-020-00173-3.CrossRefPubMedPubMedCentral

203.

Ihara H, Mitsuishi Y, Kato M, et al. Nintedanib inhibits epithelial–mesenchymal transition in A549 alveolar epithelial cells through regulation of the TGF-β/Smad pathway. Respir Investig. 2020;58:275–84. https://doi.org/10.1016/j.resinv.2020.01.003.CrossRefPubMed

Title: The effects of epithelial–mesenchymal transitions in COPD induced by cigarette smoke: an update
Authors: Xiaoshan Su
Weijing Wu
Zhixing Zhu
Xiaoping Lin
Yiming Zeng
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Lung Cancer
Lung Cancer
Smoking and Nicotine Detoxification
Chronic Obstructive Lung Disease
Lung Cancer
Published in: Respiratory Research / Issue 1/2022
Electronic ISSN: 1465-993X
DOI: https://doi.org/10.1186/s12931-022-02153-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Iron in airway macrophages and infective exacerbations of chronic obstructive pulmonary disease

Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study

Diagnostic and prognostic value of ventilatory power in pulmonary hypertension

The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients with COPD

Chinese never smokers with adenocarcinoma of the lung are younger and have fewer lymph node metastases than smokers

Did COVID-19 impact Positive Airway Pressure adherence in 2020? A cross-sectional study of 8477 patients with sleep apnea

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage